Alivus Life Sciences Ltd share price logo

Alivus Life Sciences Ltd

NSE: ALIVUS

BSE: 543322

Small Cap

Pharma Sector

₹1417.20

+19.80

(+1.42%)

as on

bell
The current prices are delayed by 15 mins, login to check live prices.

Tech Chart

🔔 Earnings Alert

Alivus reports Q2 net profit of Rs 1.97b, revenue Rs 6.82b, and EBITDA Rs 2.65b with 38.88% margin, all up year-on-year.

What are INDmoney investors doing with Alivus Life Sciences shares?

Based on platform-user behaviour - not analyst opinion or company fundamentals.

Search interest on INDmoney

-60%

Searches for Alivus Life Sciences on INDmoney have decreased by 60% over the last 30 days.

Among the most traded stocks

91st

Alivus Life Sciences was the 91st most traded stock on INDmoney over the last 7 days.

Average holding period of indmoney investors

35 days

INDmoney investors hold Alivus Life Sciences shares for an average of 35 days.

Key Events for Alivus Life Sciences

Last Dividend Declared

₹5.00 per share, declared on 14/05/2026

View Dividend History

Alivus Life Sciences Stock Performance

as on October 30, 2026 at 4:38 pm IST

  • Day's Low

    Day's High

    ₹1,415.00
    ₹1,499.00
    downward going graph

    0.16%

    Downside

    5.77%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    ₹819.00
    ₹1,499.00
    downward going graph

    42.21%

    Downside

    5.77%

    Upside

    downward going graph

Alivus Life Sciences share price movements today

Previous Close
₹1,397.40
Open
₹1,417.80
Volume
7.38L
Upper Circuit
₹1,676.80
Lower Circuit
₹1,118.00
Day's Low - High
₹1,415.00 - ₹1,499.00
52 Week Low - High
₹819.00 - ₹1,499.00

Alivus Life Sciences Historical Returns

1 Month Return
+ 1.31 %
3 Month Return
+ 27.53 %
1 Year Return
+ 53.92 %
3 Year Return
+ 125.46 %
5 Year Return
+ 123.44 %

Alivus Life Sciences Fundamentals

as on October 30, 2026 at 11:08 am IST

Market Cap

₹17,156.08 Cr

Return on Equity (ROE)

18.36

PE Ratio (TTM)

25.62

Return on capital employed (ROCE)

23.95

Industry PE ratio

51.39

Beta (LTM)

0.6

P/B Ratio

3.59

Dividend Yield

0

PEG Ratio

2.27

Quarterly Earnings Growth YOY

51.31

EPS (TTM)

0

Book Value

0

Alivus Life Sciences Stock Valuation

as on October 30, 2026 at 11:08 am IST

Alivus Life Sciences in the last 5 years

  • Overview

  • Trends

Lowest (10.31x)

March 31, 2023

Today (25.62x)

October 29, 2026

Industry (51.39x)

October 29, 2026

Highest (35.94x)

September 16, 2024

LowHigh

Today’s Price to Earnings Ratio: 25.62x

Alivus Life Sciences Technical Analysis

Track how Alivus Life Sciences technical analysis has moved over time to understand its trends.

1 min
5 min
15 min
30 min
1 day
1 week
1 month

Technicals Summary

Bearish

Neutral

Bullish

Bearish

Moving Averages

Bearish

Neutral

Bullish

Bearish

Oscillators

Bearish

Neutral

Bullish

Bearish

Overall

Bearish11
Bullish2
Neutral2

Oscillators

Name

Value

Action

MACD level (12,26)
-1.2
Bullish
CCI (20)
639.59
Bearish
RSI (14)
44.87
Neutral
Momentum (10)
-1.4
Bearish
ADI (14)
18.55
Neutral
Ultimate Oscillator (7,14,28)
10.25
Bearish

Moving Averages

Name

Value

Action

SMA (20)
1417.46
Bearish
EMA (20)
1417.47
Bearish
VWMA (20)
1416.91
Bullish
SMA (50)
1420.5
Bearish
EMA (50)
1420.64
Bearish
SMA (200)
1422.22
Bearish
EMA (200)
1422.01
Bearish
KAMA (200)
1422.76
Bearish
DEMA (200)
1428.29
Bearish

Alivus Life Sciences Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Alivus Life Sciences with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
Alivus Life Sciences Ltd image
Alivus Life Sciences Ltd
BUY17,156.0824.69%0.005642,551
Medico Intercontinental Ltd image
Medico Intercontinental Ltd
NA25.00-8.88%0.76-1284
Zenith Health Care Ltd image
Zenith Health Care Ltd
NA20.90-9.13%0.00NA10
Acutaas Chemicals Ltd image
Acutaas Chemicals Ltd
BUY32,557.69129.15%0.533561,339
Windlas Biotech Ltd image
Windlas Biotech Ltd
NA1,905.5539.05%0.5366904
See all

Market expectation of Alivus Life Sciences Stock

Common consensus of the market based on various publicly available news, publications,brokerage expectation and market data

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Alivus Life Sciences Ltd Quarterly Profit & Loss

Figures in Rupees Crores

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Sales
572.8
536.6
588.62
506.88
641.84
649.55
601.85
587.98
672.89
689.12
640.41
681.99
Other Income
1.69
3.13
5.49
8.53
10.46
10.09
8.99
14.72
13.93
22.78
22.4
19.92
Total Income
574.5
539.73
594.11
515.41
652.3
659.63
610.83
602.7
686.82
711.9
662.82
701.9
Expenses
400.25
395.15
429.13
372.52
451.54
451.11
429.54
408.81
467.27
474.59
428.7
416.8
Operating Profit
172.55
141.45
159.49
134.36
190.3
198.44
172.31
179.17
205.62
214.53
211.71
265.19
Operating Profit Margin %
30.12%
26.36%
27.1%
26.51%
29.65%
30.55%
28.63%
30.47%
30.56%
31.13%
33.06%
38.88%
Profit Before Interest, Tax and Depreciation
174.25
144.58
164.98
142.89
200.76
208.52
181.3
193.89
219.54
237.31
234.12
285.1
Interest
0.39
0.36
0.35
0.34
0.46
1.26
1.25
1.32
1.49
1.31
1.31
1.31
Depreciation
13.18
14.53
14.39
15.09
15.16
15.97
17.06
18.44
19.66
20.2
20.59
21.82
Profit Before Tax
160.68
129.69
150.24
127.46
185.14
191.29
162.99
174.13
198.39
215.8
212.22
261.97
Tax Paid
41.92
31.74
38.76
32.14
48.19
49.43
41.45
44.11
48.13
53.14
52.14
65.23
Profit After Tax
118.77
97.94
111.48
95.32
136.96
141.87
121.54
130.03
150.26
162.66
160.08
196.75
Total Net profit including share of profit / Loss from associate company
118.77
97.94
111.48
95.32
136.96
141.87
121.54
130.03
150.26
162.66
160.08
196.75
EPS
9.69
7.99
9.1
7.78
11.18
11.57
9.91
10.6
12.25
13.23
13.04
16.02
Actual EPS
9.69
7.99
9.1
7.78
11.18
11.57
9.91
10.6
12.25
13.23
13.04
16.02
Adjusted EPS
9.69
7.99
9.1
7.78
11.18
11.57
9.91
10.6
12.25
13.23
13.04
16.02
Diluted EPS
9.67
7.97
9.08
7.75
11.14
11.55
9.88
10.58
12.22
13.22
13.01
15.98

Alivus Life Sciences Ltd Annual Profit & Loss

Figures in Rupees Crores

Mar 2019
Mar 2020
Mar 2021
Sales
886.42
1,537.31
1,885.17
Other Income
0.44
11.99
0.81
Total Income
886.87
1,549.3
1,885.98
Expenses
638.7
1,065.35
1,294.09
Operating Profit
247.72
471.96
591.08
Operating Profit Margin %
27.95%
30.7%
31.35%
Profit Before Interest, Tax and Depreciation
248.16
483.95
591.89
Interest
0.61
33.52
87.55
Depreciation
19.26
29.37
33.39
Profit Before Tax
228.29
421.06
470.95
Tax Paid
32.71
107.97
119.37
Profit After Tax
195.59
313.1
351.58
Total Net profit including share of profit / Loss from associate company
195.59
313.1
351.58
EPS
24.64
29.04
32.61
Actual EPS
24.64
29.04
32.61
Adjusted EPS
0.45
0.53
2.96
Diluted EPS
24.64
29.04
32.61

Alivus Life Sciences Ltd Cash Flow

Figures in Rupees Crores

Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Net Cash from Operating Activities
-0.48
10.35
195.01
388.11
597.59
306.01
413.52
391.52
565.41
Cash Flow from Investing Activities
-
-8.84
-50.52
-68.74
-122.22
-146.75
-116.48
-615.65
-570.15
Cash Flow from Financing Activities
0.49
0.53
-136.55
-213.78
-78.8
-387.6
-279.45
-6.23
-64.34
Net Cash Flow
0.01
2.05
7.94
105.6
396.56
-228.33
17.59
-230.35
-69.08

Alivus Life Sciences Stock Shareholding Pattern

Numbers in percentages

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Promoters
82.85%
82.85%
82.85%
75%
75%
74.99%
74.94%
74.91%
74.91%
74.87%
74.87%
74.85%
DII
0.59%
1.4%
1.57%
4.16%
4.86%
5.19%
5.61%
5.47%
7.12%
7.28%
7.18%
7.03%
FII
0%
5.01%
4.82%
7.85%
6.74%
6.57%
6.42%
6.84%
5.09%
5.29%
5.54%
5.93%
Public
11.84%
10.73%
10.76%
12.98%
13.4%
13.25%
13.03%
12.78%
12.88%
12.56%
12.41%
12.19%
Total Outstanding Shares
12,25,27,172
12,25,27,172
12,25,27,172
12,25,28,672
12,25,32,862
12,25,37,052
12,26,29,148
12,26,81,348
12,26,81,348
12,27,36,348
12,27,39,448
12,27,71,448
Total Shareholders
1,85,531
1,56,183
1,49,396
1,43,960
1,46,840
1,41,977
1,38,500
1,35,643
1,32,748
1,27,969
1,25,559
1,22,777

Mutual Funds Buying / Exiting Alivus Life Sciences

Holdings as of 15 Oct 2026 · based on the latest SEBI-mandated portfolio disclosures

Mutual Funds Buying Alivus Life Sciences

Sorted by largest increase in holding, month-over-month.

Fund Name

Value of Holding

Increase (MoM)

Holding %

Bandhan Large & Mid Cap Fund Direct Plan Growth

Bandhan Large & Mid Cap Fund Direct Plan Growth

₹128.77 Cr

₹12.94 Cr (+11.17%)

0.61%

Old Bridge Focused Fund Direct Growth

Old Bridge Focused Fund Direct Growth

₹187.00 Cr

₹11.60 Cr (+6.61%)

4.01%

Mutual Funds Exiting Alivus Life Sciences

Sorted by largest decrease in holding, month-over-month.

Fund Name

Value of Holding

Decrease (MoM)

Holding %

ICICI Prudential Healthcare Fund Direct Growth

ICICI Prudential Healthcare Fund Direct Growth

₹68.09 Cr

₹17.14 Cr (-20.11%)

0.97%

Alivus Life Sciences Corporate Actions

View detailed summary of the earnings and dividend history of Alivus Life Sciences.

  • Alivus Life Sciences Ltd Earnings Results

    Alivus Life Sciences Ltd’s net profit jumped 31.71% since last year same period to ₹160.08Cr in the Q1 2026-2027. On a quarterly growth basis, Alivus Life Sciences Ltd has generated -1.59% fall in its net profits since last 3-months.

    Read More

  • Alivus Life Sciences Ltd Dividends May,2026

    In the quarter ending March 2026, Alivus Life Sciences Ltd has declared dividend of ₹5.00 per share on 14 May 2026 - translating a dividend yield of 0.36%.

    Read More about Dividends

Indices Featuring Alivus Life Sciences Stock

Check stock indices that include Alivus Life Sciences.

BSE Healthcare

₹50,128.49

+434.20 (▲0.87%)

Insights on Alivus Life Sciences Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, ALIVUS stock has moved up by 10.3%

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 5.54% to 5.93% in Sep 2026 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Laurus Labs Ltd has given 126.9% return, outperforming this stock by 72.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Laurus Labs Ltd has given 503.8% return, outperforming this stock by 378.0%

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 5.65% to 5.29% in Sep 2026 quarter

  • imgNEGATIVE IMPACT

    Promoter Holding Down

    img

    Promoters have decreased holdings from 74.87% to 74.85% in Sep 2026 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 12.41% to 12.19% in Sep 2026 quarter

About Alivus Life Sciences Ltd

Glenmark Life Sciences Private Limited (formerly Zorg Laboratories Private Limited) was incorporated as a private limited company on 23 June 2011. It was acquired by Glenmark Pharmaceuticals Limited in July 2018, and was converted to a public company in August 2018. Operating as a wholly-owned subsidiary of Glenmark Pharmaceuticals, the company is engaged in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs). The company has Research and Development (R&D) facilities in Mahape, Ankleshwar, and Dahej, while its manufacturing facilities are located in Ankleshwar, Dahej, Mohol, and Kurkumbh. On 13 August 2018, Glenmark Life Sciences allotted 4,500,090 equity shares of Rs. 10 each upon conversion of a loan given to the Director, and 15,000,000 shares to its parent company Glenmark Pharmaceuticals under preferential allotment. The company recently concluded its IPO, of a total of 21,022,222 equity shares, raising Rs. 15136 million. All of the outstanding purchase consideration was repaid from the proceeds of the IPO, and the company’s equity shares are now listed on both the BSE and NSE.

Revenue: ₹681.99Cr as on September 2026 (Q2 FY27)
Net Profit: ₹196.75Cr as on September 2026 (Q2 FY27)
Listing date: 06 Aug, 2021
Chairperson Name: Glenn Saldanha
OrganisationAlivus Life Sciences Ltd
IndustryPharmaceuticals
CEOGlenn Saldanha
E-voting on sharesClick here to vote

FAQs

What is Alivus Life Sciences share price today?

Alivus Life Sciences share price today stands at ₹1417.2 as on . Alivus Life Sciences share today touched a day high of ₹1499 and a low of ₹1415.

What is the 52 week high and 52 week low range for Alivus Life Sciences share?

Alivus Life Sciences touched a 52 week high of ₹1499 and a 52 week low of ₹819. Alivus Life Sciences share price today i.e. is trending at ₹1417.2, which is -5.46% down from its 52 week high and 73.04% up from its 52 week low.

What is Alivus Life Sciences's market capitalisation today?

Alivus Life Sciences market capitalisation is ₹17,156.08 Cr as on .

How to buy Alivus Life Sciences shares?

To buy Alivus Life Sciences shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for ALIVUS or Alivus Life Sciences Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in Alivus Life Sciences shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is Alivus Life Sciences trading volume today?

Alivus Life Sciences trading volume is 7.38L as on . This means that 7.38L shares of Alivus Life Sciences were bought and sold on the stock market during today's trading session.